Notice Number: NOT-DK-09-006

Key Dates
Release Date: April 23, 2009

Issued by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), (http://www2.niddk.nih.gov)

Purpose: The purpose of this request for information (RFI) is to gather information from the scientific community about current needs and emerging opportunities in therapeutics development for type 1 diabetes (T1D) prevention and treatment.  The National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) seeks to identify new therapeutic or intervention strategies currently under development that may be facilitated by expanded in vivo efficacy preclinical testing.

Background: As part of its mission to facilitate therapeutics development along the translational continuum, the NIDDK has established a contract to support expanded preclinical testing for therapies to prevent or reverse type 1 diabetes (http://www.t1diabetes.nih.gov/T1D-PTP/). The contract supports the resources and expertise needed to acquire expanded preclinical therapeutic efficacy data in rodent models of T1D.

Information is needed to gauge specific needs of the investigator community for these services.

Information Requested: We seek to identify scientists with promising new therapeutics or intervention strategies in early stages of development that may require further efficacy testing in rodent models.  Investigators working in T1D with preclinical testing needs (proponents) should respond to this RFI by providing a brief description of the intervention concept and relevant preliminary data supporting therapeutic promise. Agents that may be used in both rodents and humans will be considered a priority.

Reponses: Please refer to this notice in any communications, and respond by email to: ga96b@.nih.gov or ss24g@nih.gov.

This RFI is for information purposes only and should not be construed as a solicitation or as an obligation on the part of the NIDDK. The NIDDK does not intend to award a grant or contract to pay for the preparation of any information submitted or for the NIDDK’s use of such information.  Responses will be held confidential.  Any proprietary information should be so marked.

Inquiries

Inquiries regarding this notice may be directed to:

Guillermo Arreaza-Rubín, M.D.
Division of Diabetes, Endocrinology, and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 6101
Bethesda, MD 20892-5460
Telephone: (301) 594-4724
FAX: (301) 480-2688
E-mail: ga96b@nih.gov

Lisa Spain, Ph.D.
Division of Diabetes, Endocrinology, and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 695
Bethesda, MD 20892-5460
Telephone: (301) 451-9871
FAX: (301) 480-2688
E-mail: ss24q@nih.gov

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.